X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
PQ912 (varoglutamstat) is designed to prevent N3pE- Abeta formation, a key driver of AD pathology. It is being developed for the treatment of alzheimer's disease.
Lead Product(s): Varoglutamstat
Therapeutic Area: Neurology Product Name: PQ912
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
PQ912 (varoglutamstat) is designed to prevent N3pE- Abeta formation, a key driver of AD pathology. It is being developed for the treatment of alzheimer's disease.
Lead Product(s): Varoglutamstat
Therapeutic Area: Neurology Product Name: PQ912
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
PQ912 (varoglutamstat) is designed to prevent N3pE- Abeta formation, a key driver of AD pathology. It is being developed for the treatment of alzheimer's disease.
Lead Product(s): Varoglutamstat
Therapeutic Area: Neurology Product Name: PQ912
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
Vivoryon intends to use the net proceeds to accelerate the ongoing clinical development of its lead product candidate PQ912 (varoglutamstat), currently in Phase 2 in Europe and the United States for the treatment of patients with Alzheimer’s disease.
Lead Product(s): Varoglutamstat
Therapeutic Area: Neurology Product Name: PQ912
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hauck Aufhäuser Lampe Privatbank AG
Deal Size: $26.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 26, 2023
Details:
PQ912 (varoglutamstat) is designed to prevent N3pE- Abeta formation, a key driver of AD pathology. It is being developed for the treatment of alzheimer's disease.
Lead Product(s): Varoglutamstat
Therapeutic Area: Neurology Product Name: PQ912
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
Varoglutamstat (PQ912) is a differentiated oral small-molecule targeting the toxic Abeta species N3pE which is being developed as disease-modifying therapy and is designed to target AD pathology upstream of Abeta-antibody focused approaches.
Lead Product(s): Varoglutamstat
Therapeutic Area: Neurology Product Name: PQ912
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nordic Bioscience
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2022
Details:
Vivoryon and the Alzheimer’s Disease Cooperative Study have developed a new trial design for Phase 2a Alzheimer’s trial in the US as a stage gate to Phase 2b. Vivoryon’s lead candidate, PQ912, got approval of the International Nonproprietary Name (INN), varoglutamstat.
Lead Product(s): Varoglutamstat
Therapeutic Area: Neurology Product Name: PQ912
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
